AN2 Therapeutics reports FY2023 net loss of $64.7M; Phase 2/3 trial paused, topline expected summer 2024

AN2 Therapeutics, Inc.

Net loss FY2023 $64.7M vs $41.0M prior year; Q4 net loss $16.9M vs $11.8M.
Cash, equivalents and investments $134.5M at Dec 31, 2023.
Phase 3 enrollment in epetraborole TR-MAC trial paused voluntarily Feb 2024 due to potentially lower efficacy; Phase 2 topline results expected summer 2024.
Plan to discuss Phase 2/3 data with FDA; no safety concerns prompted pause.
Executed license from UGA for Chagas disease candidate AN2-502998; Gates Foundation grant for TB/malaria.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AN2 Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year. Net loss for the fourth.

Period: the fourth quarter and year ended December 31, 2023
Net income: Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year. Net loss for the fourth
Result: reported results

Exact text from the filing

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-038055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.